French pharmaceutical giant Servier is acquiring an experimental muscular dystrophy treatment from Edgewise Therapeutics in a deal worth $1.55 billion upfront. The transaction centers on sevasemten, a drug candidate still in clinical development.
The acquisition marks a significant bet by Servier on the rare disease space, particularly for Duchenne muscular dystrophy, a severe genetic disorder that causes progressive muscle degeneration. The upfront payment underscores the high value placed on potential therapies targeting this underserved condition.
Edgewise Therapeutics will receive the $1.55 billion upfront, though additional details on potential milestone payments were not disclosed. The deal structure suggests Servier is confident in sevasemten's clinical prospects, which have shown promise in early-stage trials.
The acquisition positions Servier to compete in the muscular dystrophy market, where current treatment options remain limited. For Edgewise, the deal provides substantial capital and access to a larger pharmaceutical infrastructure for further development and commercialization.
Critics caution that sevasemten has not yet completed pivotal trials, and the high upfront cost carries risk if the drug fails to meet efficacy endpoints or gain regulatory approval.